Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641041 | 0.83 | TAAR1 (0.55) | TAAR1IDO1AGXTCYP1A2CYP2D6 | |
| SCHEMBL21187234 | 0.83 | TAAR1 (0.55) | TAAR1IDO1AGXTCYP1A2CYP2D6 | |
| SCHEMBL30174362 | 0.82 | PNMT (0.60) | TAAR1IDO1AGXTSLC6A4SIGMAR1 | |
| SCHEMBL21583913 | 0.82 | PNMT (0.60) | TAAR1IDO1AGXTSLC6A4SIGMAR1 | |
| SCHEMBL7473544 | 0.82 | PNMT (0.60) | TAAR1IDO1AGXTSLC6A4SIGMAR1 | |
| SCHEMBL30457687 | 0.82 | PNMT (0.60) | TAAR1IDO1AGXTSLC6A4SIGMAR1 | |
| SCHEMBL552963 | 0.82 | TAAR1 (0.55) | TAAR1IDO1AGXTCYP1A2CYP2D6 | |
| SCHEMBL1177558 | 0.81 | TAAR1 (0.48) | TAAR1IDO1AGXTSLC6A4SIGMAR1 | |
| SCHEMBL4853320 | 0.81 | TAAR1 (0.48) | TAAR1IDO1AGXTSLC6A4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL30559563 | 0.81 | PNMT (0.58) | TAAR1IDO1AGXTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | TAAR1 781/4885IDO1 313/4885AGXT 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.